Angiotech Pharmaceutical Inc. (OTC:ANPI) is giving its creditors a few more days to mull over a settlement that would pay them pennies on the dollar for their stakes in the bankrupt firm.
The Vancouver-based maker of paclitaxel, the drug used in Boston Scientific Corp.’s (NYSE:BSX) Taxus coronary stents, filed for bankruptcy in late January. The Supreme Court of British Columbia approved a bankruptcy plan, aimed at eliminating $250 million in debt under Canada’s Companies’ Creditors Arrangement Act. The plan will largely wipe out the company’s existing shareholders, apart from a group connected with its 2006 acquisition of Quill Medical Inc.
Angiotech said in regulatory filings that it will give creditors with claims of $5,000 to $31,250 10 days to decide whether to accept a $5,000 cash settlement. Creditors owed more than $31,250 can elect to receive a cash settlement of 16 cents on the dollar, up to $24,000. The countdown is slated to begin today, coincident with Angiotech’s annual shareholders meeting.
The deadlines do not affect holders of the company’s 7.75 percent senior subordinated notes due 2014.
Angiotech officials said recently that its net losses widened during the three months ended Dec. 31, 2010, rising to $11.8 million.
The company attributed the losses to a continued, downward slide of royalty revenues from Taxus sales, which declined by 59 percent during the quarter to just more than $6 million (compared to $13.5 million during Q4 2009). Angiotech reaps around 6 percent of the net sales of Taxus stents worldwide from royalties for BSX’s use of its product.
Since hitting a high-water mark in 2005, Angiotech’s royalty revenues from paclitaxel-eluting coronary devices have plummeted in subsequent years.
Boston Scientific is still the worldwide leader in drug-eluting stents, but a steady increase in competition from other DES makers like Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ) subsidiary Cordis Corp. and Medtronic Inc. (NYSE:MDT) has cut into those sales significantly.
ANPI stock was de-listed from the Toronto Stock Exchange March 3, after it failed to meet the market’s trading requirements.
